4.6 Article

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms:: a study of the PETHEMA group

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 114, Issue 1, Pages 99-103

Publisher

BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-2141.2001.02915.x

Keywords

acute promyelocytic leukaemia; PML/RAR alpha isoform; clinical outcome; complete remission; all-trans retinoic acid (ATRA); reverse transcription-polymerase chain reaction (RT-PCR)

Categories

Ask authors/readers for more resources

Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)-form (50%), eight variable (V)-form (5%) and 76 short (S)-form (45%). The V-form and S-form groups presented a significantly higher percentage of patients with white blood cell counts > 10 x 10(9)/l (P < 0.05). The S-form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0.005) and CD34 expression (P < 0.0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3-year disease-free survival was lower for V-form cases than it was for L- and S-form cases (62% vs. 94% and 89%, P = 0.056). We conclude that the V-form and S-form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V-form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available